Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein

Immunological Reviews

Volumn 169, Issue , 1999, Pages 147-159

  Goverman, Joan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; EPITOPE; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL FATE; CELL MATURATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; HEREDITY; IMMUNOLOGICAL TOLERANCE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE TOLERANCE; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; RECEPTORS, ANTIGEN, T-CELL;

EID: 0032795286     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01313.x     Document Type: Review

References (111)

1. 1. Raine CS. The neuropathology of multiple sclerosis. In: Raine CS, McFarland HF. Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenetic basis. London: Chapman & Hall; 1997, p. 151-171.
2. 2. Duquette P, Pleines J, Girard M, Chirest L, Senecal QM, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992;19:466-471.
3. 3. Martin R, McFarland HF. Immunology of multiple sclerosis and experimental allergic encephalomyelitis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenic basis. London: Chapman & Hall; 1997, p. 221-242.
4. 4. Sadovnick AD, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993:33:281-285.
5. 5. McFarland HF, Martin R, McFarlin DE. Genetic influences in multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenic basis. London: Chapman & Hall; 1997, p. 205-219.
6. 6. Kurtzke JF. The epidemiology of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenic basis, London: Chapman & Hall; 1997, p. 91-139.
7. 7. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
8. 8. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-422.
9. 9. Sibley WA, Barnford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1(8441):1313-1315.
10. 10. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with γ interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102.
11. 11. Ter Meulen V, Katz M. The proposed viral etiology of multiple sclerosis and related demylinating diseases. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenic basis. London: Chapman & Hall; 1997. p. 287-305.
12. 12. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-187.
13. 13. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985;230:1043-1045.
14. 14. Jahnke U, Fisher EH, Alvord EC Jr. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis. Science 1985;229:282-287.
15. 15. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
16. 16. Talbot PJ, Paquette JS, Ciurli C, Antel JP, Quellet F. Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neurol 1996:39:233-240.
17. 17. Paterson PY. Experimental autoimmune (allergic) encephilomyelitis: induction, pathogenesis, and suppression. In: Mescher PA, Mueller-Eberhard HS, eds. Textbook of immunopathology. New York: Grune and Stratton: 1976. p. 179-213.
18. 18. Raine CS. The lesion in multiple sclerosis and chronic relapsing experimental allergic encephalomyelitis: a structural camparison. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple sclerosis: clinical and pathogenic basis. London: Chapman & Hall; 1997. p. 243-286.
19. 19. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vivo activation of lymph node cells by myelin basic protein: requirement for Lyt-1-2+ T lymphocytes. J Immunol 1981;127:1420-1423.
20. 20. Paterson PY, Swanborg RH. Demyelinating diseases of the central and peripheral nervous systems. In: Samter M, Talmage DW, Frank MM, Austen KF, Claman HN, eds. Immunological diseases. 4th ed. Boston (MA): Little Brown and Co; 1988. p. 1877-1912.
21. 21. Zamvil SS. Steinman I., The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-621.
22. 22. Zamvil SS. Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986;324:258-260.
23. 23. Urban IL, et al. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988:54:577-592.
24. 24. Acha Orbea H, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988;54:263-273.
25. 25. Zamvil SS, Mitchell DJ, Powell MB, Sakai K, Rothbard JB, Sieinman L. Multiple discrete encephalitogenic epitopes of the autoantigen myelin basic protein include a determinant for I-E class II-restricted T cells. J Exp Med 1988;168:1181-1186.
26. 26. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an auto-antigen. Nature 1992:358:155-157.
27. 27. Tuohy VK, Lu Z, Sobel RA, Laursen RA, Lees MB. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 1989;142:1523-1527.
28. 28. Sakai K, Zamvil SS, Mitchell DJ, Lim M, Rothbard JB, Steinman L. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 1988;19:21-32.
29. 29. Brown AM, McFarlin DE. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest Methods Cell Biol 1981;45:278-284.
30. 30. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85.
31. 31. Raine CS, Cannella B, Duijvestijn AM, Cross AH. Homing to central nervous system vasculature by antigen specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest 1990;63:476-489.
32. 32. Cannella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991;65:23-31.
33. 33. Steffen BJ, Butcher EC, Engelhardt B, Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 1994:145:189-201.
34. 34. O'Neill JK, et al. Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Immunology 1991:72:520-525.
35. 35. Wekerle H, Engelhardt B, Risau W, Meyermann R. Interaction of T lymphocytes with cerebral endothelial cells in vitro. Brain Pathol 1991;1:107-114.
36. 36. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR, Hofman FM. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and BIO.PT, mice. Proc Natl Acad Sci USA 1992:89:574-578.
37. 37. Renno T, Lin J-Y, Piccirillo C, Antel J, Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol 1994;49:1-7.
38. 38. Karpus WJ, et al. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-5010.
39. 39. Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β. J Neuroimmunol 1995:61:205-212.
40. 40. Issazadeh S, Lorentzen JC, Mustafa MI, Hojeberg B, Mussener A, Olsson T. Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats; persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β. J Neuroimmunol 1996;69;103-115.
41. 41. Renno T, Krakowski M, Piccirillo C, Lin J-Y, Owens T. TNF-α expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. J Immunol 1995:154:944-953.
42. 42. Crisi GM, Santambrogio L, Hochwald GM, Smith SR, Carlino JA, Thorbecke GJ. Staphylococcal enterotoxin B and tumornecrosis factor-α-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-β and interleukin-10. Eur J Immunol 1995;25:3035-3040.
43. 43. Powell MB. et al. Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990;2:539-544.
44. 44. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988:23:339-346.
45. 45. Chung IY, Norris JG, Benveniste EN. Differential tumor necrosis factor α expression by astrocytes from experimental allergic encephalomyelitis-susccptible and resistant rat strains. J Exp Med 1991;173:801-811.
46. 46. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992:149:2496-2505.
47. 47. Owens T, Renno T, Taupin V, Krakowski M. Inflammatory cytokines in the brain: does the CNS shape immune response? Immunol Today 1994;15:566-571.
48. 48. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-1364.
49. 49. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD. Differential expression of inflammatory cylokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998:161:4437-4446.
50. 50. Van der Veen RC, Stohlman SA. Encephalilogenic Th 1 cells are inhibited by Th2 cells with related peptide specificity; relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol 1993:48:213-220.
51. 51. Chen Y, Kuchroo V, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance and suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
52. 52. Kuchroo VK, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1994,80:707-718.
53. 53. Khoruts A, Miller SD, Jenkins MK. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 1995,155:5011-5017.
54. 54. Lafaille JJ, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186:307-312.
55. 55. Bauer J, Wekerle H, Lassmann H. Apoptosis in brain-specific autoimmune disease. Curr Opin Immunol 1995;7:839-843.
56. + encephalitogenic T cells. Eur J Immunol 1994:24:2609-2617.
57. 57. Pender MP, McCombe PA, Yoong G, Nguyen KB. Apoptosis of αβ T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: its possible implications for recovery and acquired tolerance. J Autoimmun 1992;5:401-410.
58. 58. Gold R, et al. Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Brain 1996,119:651-659.
59. 59. Ruddle NH, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172;1193-1200.
60. 60. Leonard JP. Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181:381-386.
61. 61. Selmaj K, Papiere W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor 1. J Neuroimmunol 1995;56:135-141.
62. 62. Sommer N, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995:1:244-248.
63. 63. Genain CP, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995;92:3601-3605.
64. 64. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
65. 65. Sommer N, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997;79:54-61.
66. 66. Racke MK, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-1966.
67. 67. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24;1434-1440.
68. 68. Racke MK, Dhib JS, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β 1. J Immunol 1991;146:3012-3017.
69. 69. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O. Macrophage-inactivating II. 13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 1994;153:4258-4267.
70. 70. Racke MK, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995;154;450-458.
71. 71. Zaller DM, Osman G, Kanagawa O, Hood L. Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V β specific antibodies. J Exp Med 1990:171:1943-1955.
72. 72. Ben NA, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981;292:60-61.
73. 73. Howell MD, Winters ST, Olee T. Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides [published erratum appears in Science 1990:247:1167]. Science 1989;246:668-670.
74. 74. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989;341;541-544.
75. 75. Brocke S, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996:379:343-346.
76. 76. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity, 1995;3:397-405.
77. 77. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production. J Exp Med 1994;180:2227-2237
78. 78. Kuchroo VK, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994;153:3326-3336.
79. 79. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991;147:2155-2163.
80. 80. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation hut not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993:5:1159-1165.
81. 81. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance [published erratum appears in Nature 1995:377:257]. Nature 1995;376:177-180.
82. 82. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein specific T cell receptor develop spontaneous autoimmunity. Cell 1993:72:551-560.
83. 83. Sant' Angelo DB, et al. A molecular map of T cell development. Immunity 1998;9:179-186.
84. 84. Offner H, Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J Immunol 1998;161:2178-2186.
85. 85. Fairchild PJ, Wildgoose R, Atherton E, Webb S, Wraith DC. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993:5:1151-1158.
86. 86. Mason K, Denney DW Jr, McConnell HM. Myelin basic protein peptide complexes with the class II MHC molecules 1-A ami 1-A1 form and dissociate rapidly at neutral pH J Immunol 1995:154:5216-5227.
87. 87. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC, Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995;3:407-415.
88. 88. Pearson CL, van Ewijk W, McDevitt HO. Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice. J Exp Med 1997;185:583-599.
89. 89. Brabb T, et al. Thymic stromal organization is regulated by the specificity of T cell receptor/major histocompatibility complex interactions. Eur J Immunol 1997:27:136-146.
90. 90. Harrington CJ, et al. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998:8:571-580.
91. 91. Bhardwaj V, et al. T cell determinant structure of myelin basic protein in B10,PI., SJL/J. and their Fls. J Immunol 1994;152:3711-3719.
92. 92. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998;187:2055-2063.
93. 93. Loltus C, Huseby ES, Gopaul P, Beeson C, Goverman J. Highly cross-reactive T cell responses to myelin basic protein epitopes reveal a non-predictable form of TCR degeneracy. J Immunol (In press).
94. 94. Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice, I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 1982;73:299 310.
95. 95. Munoz JJ, Bernard CC, Mackay IR. Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell Immunol 1984;83:92-100.
96. 96. Brabb T, Goldrath AW, von Dassow P, Paez A, Liggitt HD, Goverman J. Triggers of autoimmune disease in a murine T-cell receptor transgenic model for multiple sclerosis. J Immunol 1997:159:497-507.
97. 97. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidente of spontaneous autoimmune, encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994;78:399-408.
98. 98. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
99. 99. Rodriguez M, Dunkel AJ, Thiemann RL, Leibowitz J, Zijlstra M, Jaenisch R. Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in β 2-microglobulin. J Immunol 1993:151:266-276.
100. 100. Encinas JA, et al. Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J Immunol 1996;157:2186-2192.
101. + T Cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J Exp Med 1998:188:1875-1882.
102. + T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med 1998;188:1883-1894.
103. α region. J Neurosci Res 1997;47:489-499.
104. 104. Siklodi B, Jacobs R, Vandenbark AA, Offner H. Neonatal exposure of TCR BV8S2 transgenic mice lo recombinant TCR BV8S2 results in reduced T cell proliferation and elevated antibody response to BV8S2, and increased severity of EAE J Neurosci Res 1998;52:750-756.
105. 105. Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991;251:430-432.
106. 106. Kumar V, Sercaiz E. Dysregulation of potentially pathogenic self reactivity is crucial lor the manifestation of clinical autoimmunity J Neurosci Res 1996;45;334-339.
107. 107. Critchfield JM, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143.
108. 108. Bochme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur J Immunol 1993;23:1552-1560.
109. 109. Marusic S, Tonegawa S. Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide. J Exp Med 1998;186:507-515.
110. 110. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway CA Jr, Weiner HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996:93:388-391.
111. 111. Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N. Treatment of autoimmune disease by oral tolerance to antoantigens. Clin Immunol Immunopathol 1996;80: S31-S39.